Can Big Pharma's moneymakers stay hot as price hikes slow down?

10th October 2018 Uncategorised 0

In a new report, Leerink Partners analyst Geoffrey Porges detailed which “signature” drugs might struggle to grow due to U.S. pricing pressure.

More: Can Big Pharma's moneymakers stay hot as price hikes slow down?
Source: fierce